A Wave of Success for Cambridge Heart
Executive Summary
For years, Cambridge Heart has been in an almost missionary mode. Since its founding in 1990, it has spent millions on R&D and sustained steady losses. But it finally looks like Cambridge Heart is well on the way to answering the two key questions for medical technology developers: clinical relevance and reimbursement. On March 21, the US Centers for Medicare & Medicaid Services issued a national coverage decision for Cambridge Heart's Microvolt T-Wave Alternans test for patients at risk of sudden cardiac death,